Haemonetics Corporation (HAE)
Official siteHEALTHCARE • MEDICAL DEVICES • NYSE
Market Cap: $5.60B
Last updated: Nov 17, 2026 at 11:06 AM ET
Haemonetics Corporation (HAE) Financials: Revenue, Profit and Cash Flow
Haemonetics reported revenue of $1.33B for the fiscal year ended Mar 31, 2026, down 2.0% from the year before. That year, net income was $97.31M with a net margin of 7.3%, operating cash flow was $293.22M and free cash flow was $260.44M. The quarter ended Sep 30, 2026 had revenue of $357.76M and net income of $46.30M.
Revenue and Margins
The operating margin was 11.7% in the fiscal year ended Mar 2026. Over the 9 years to Mar 2026, revenue grew from $886.12M, a compound annual rate of 4.6%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Mar 2026 | $1.33B | -2.0% | 59.0% | 11.7% | 7.3% |
| Mar 2025 | $1.36B | +4.0% | 55.0% | 16.3% | 12.3% |
| Mar 2024 | $1.31B | +12.0% | 52.8% | 12.6% | 9.0% |
| Mar 2023 | $1.17B | +17.7% | 52.6% | 13.4% | 9.9% |
| Mar 2022 | $993.20M | +14.1% | 50.9% | 8.1% | 4.4% |
| Mar 2021 | $870.46M | -11.9% | 45.7% | 10.3% | 9.1% |
| Mar 2020 | $988.48M | +2.2% | 49.0% | 10.5% | 7.7% |
| Mar 2019 | $967.58M | +7.0% | 43.2% | 8.6% | 5.7% |
| Mar 2018 | $903.92M | +2.0% | 45.6% | 6.2% | 5.0% |
| Mar 2017 | $886.12M | N/A | 42.7% | -2.2% | -3.0% |
Income Statement
In the fiscal year ended Mar 2026, net income fell 42.0% from the year before. In the quarter ended Sep 2026, net income rose 19.7% from the same quarter a year earlier.
Annual
| Line item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.33B | $1.36B | $1.31B | $1.17B | $993.20M | $870.46M | $988.48M | $967.58M | $903.92M | $886.12M |
| Cost of revenue | $546.44M | $611.87M | $617.51M | $553.56M | $487.69M | $472.63M | $503.97M | $550.04M | $492.01M | $507.62M |
| Gross profit | $787.59M | $748.96M | $691.55M | $615.10M | $505.50M | $397.84M | $484.51M | $417.54M | $411.91M | $378.49M |
| Research and development | $59.77M | $62.72M | $54.44M | $50.13M | $46.80M | $32.86M | $30.88M | $35.71M | $39.23M | $37.56M |
| Operating income | $156.73M | $221.82M | $164.88M | $156.03M | $80.75M | $89.75M | $103.35M | $83.55M | $56.16M | -$19.38M |
| Net income | $97.31M | $167.68M | $117.56M | $115.40M | $43.38M | $79.47M | $76.53M | $55.02M | $45.57M | -$26.27M |
| EBITDA | $245.56M | $342.61M | $252.43M | $234.71M | $164.78M | $157.76M | $198.04M | $183.05M | $148.88M | $62.26M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $357.76M | $339.38M | $346.35M | $338.97M | $327.31M | $321.39M | $330.60M | $348.54M | $345.51M | $336.17M | $343.29M | $336.25M |
| Gross profit | $220.91M | $202.80M | $198.21M | $202.39M | $194.74M | $192.24M | $193.05M | $193.55M | $187.44M | $174.92M | $175.91M | $177.87M |
| Operating income | $75.12M | $57.46M | -$23.02M | $67.40M | $58.49M | $53.87M | $71.33M | $59.03M | $51.70M | $39.76M | $29.94M | $45.98M |
| Net income | $46.30M | $33.01M | -$20.15M | $44.74M | $38.68M | $34.03M | $57.98M | $37.49M | $33.83M | $38.37M | $20.37M | $31.24M |
Balance Sheet
As of Mar 2026, total debt of $1.22B exceeded cash and equivalents by $979.14M.
Annual
| Line item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $2.40B | $2.45B | $2.20B | $1.93B | $1.86B | $1.82B | $1.27B | $1.27B | $1.24B | $1.24B |
| Current assets | $834.88M | $934.98M | $768.90M | $769.72M | $756.03M | $693.55M | $603.64M | $576.12M | $521.18M | $510.03M |
| Cash and equivalents | $245.44M | $306.76M | $178.80M | $284.47M | $259.50M | $192.31M | $137.31M | $169.35M | $180.17M | $139.56M |
| Total liabilities | $1.60B | $1.63B | $1.24B | $1.12B | $1.11B | $1.09B | $680.00M | $606.90M | $484.91M | $499.10M |
| Short-term debt | $5.01M | $303.56M | $10.23M | $11.78M | $214.15M | $17.02M | $76.98M | $27.67M | $194.26M | $61.02M |
| Long-term debt | $1.22B | $921.23M | $797.56M | $754.10M | $559.44M | $690.59M | $305.51M | $322.45M | $59.42M | $253.63M |
| Shareholder equity | $796.32M | $820.84M | $959.96M | $818.00M | $749.42M | $731.67M | $587.11M | $667.87M | $752.43M | $739.61M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $2.41B | $2.37B | $2.40B | $2.49B | $2.44B | $2.46B | $2.45B | $2.53B | $2.53B | $2.54B | $2.20B | $2.20B |
| Total liabilities | $1.51B | $1.53B | $1.60B | $1.58B | $1.59B | $1.58B | $1.63B | $1.62B | $1.65B | $1.64B | $1.24B | $1.26B |
| Cash and equivalents | $260.71M | $223.38M | $245.44M | $363.37M | $296.43M | $292.90M | $306.76M | $320.85M | $299.28M | $344.43M | $178.80M | $193.98M |
| Shareholder equity | $898.50M | $837.10M | $796.32M | $911.45M | $849.17M | $882.30M | $820.84M | $906.86M | $878.85M | $905.37M | $959.96M | $943.32M |
Cash Flow
In the fiscal year ended Mar 2026, free cash flow was 88.8% of operating cash flow. Share repurchases came to 67.2% of it.
Annual
| Line item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $293.22M | $181.72M | $181.75M | $273.06M | $172.26M | $108.81M | $158.22M | $159.28M | $220.35M | $159.74M |
| Capital expenditures | $32.78M | $39.28M | $38.13M | $191.33M | $96.51M | $37.04M | $48.76M | $118.96M | $74.80M | $76.14M |
| Free cash flow | $260.44M | $142.45M | $143.63M | $81.73M | $75.75M | $71.77M | $109.46M | $40.32M | $145.55M | $83.60M |
| Dividends paid | N/A | N/A | N/A | $7.02M | N/A | N/A | $12.02M | $13.45M | $0 | $0 |
| Share repurchases | $175.00M | $225.00M | $0 | $75.00M | $0 | $0 | $175.00M | $160.00M | $100.00M | $0 |
| Investing cash flow | -$179.55M | -$161.90M | -$322.39M | -$143.79M | -$86.34M | -$425.44M | -$57.18M | -$116.15M | -$63.04M | -$73.31M |
| Financing cash flow | -$178.46M | $108.82M | $38.16M | -$100.36M | -$15.75M | $367.45M | -$131.21M | -$50.63M | -$120.64M | -$60.41M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $128.10M | $52.32M | $70.94M | $93.56M | $111.32M | $17.39M | $116.56M | $43.77M | $48.82M | -$27.42M | $64.08M | -$540.00K |
| Capital expenditures | $14.77M | $7.91M | $17.66M | $6.35M | $5.02M | $3.75M | $15.64M | $8.55M | $9.43M | $5.66M | $6.68M | $14.65M |
| Free cash flow | $113.33M | $44.42M | $53.28M | $87.22M | $106.31M | $13.64M | $100.91M | $35.22M | $39.39M | -$33.08M | $57.40M | -$15.19M |
Frequently Asked Questions About HAE
What is Haemonetics' annual revenue?
Haemonetics reported revenue of $1.33B for the fiscal year ended Mar 31, 2026.
How fast is Haemonetics' revenue growing?
Revenue was down 2.0% for the fiscal year ended Mar 31, 2026 compared with the year before. The compound annual revenue growth rate over 3 years was 4.5%.
Is Haemonetics profitable?
Yes. Haemonetics reported net income of $97.31M for the fiscal year ended Mar 31, 2026, with a net margin of 7.3%.
How much free cash flow does HAE generate?
For the fiscal year ended Mar 31, 2026, operating cash flow of $293.22M minus capital expenditures of $32.78M produced free cash flow of $260.44M.
How much debt does Haemonetics have?
The balance sheet dated Mar 31, 2026 reported long-term debt of $1.22B, short-term debt of $5.01M and cash and equivalents of $245.44M.
HAE pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts